Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder	Not yet recruiting	Phase 2	2026-05-20		NCT07593040

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Vall d'Hebron Institute of Oncology	18

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Complejo Hospitalario Universitario De Ourense	Ourense	Spain	1
Hospital Clinic de Barcelona	Barcelona	Spain	11
Hospital Clinico Universitario Lozano Blesa	Zaragoza	Spain	5
Hospital Universitari Vall d Hebron	Barcelona	Spain	38
Hospital Universitario 12 de Octubre	Madrid	Spain	55
Hospital Universitario Central de Asturias	Oviedo	Spain	57
Hospital Universitario de Navarra	Pamplona	Spain	33
Hospital Universitario Lucus Augusti	Lugo	Spain	7
Hospital Universitario Marques de Valdecilla	Santander	Spain	38
Hospital Universitario Ramon y Cajal	Madrid	Spain	10
Hospital Universitario Reina Sofia	Córdoba	Spain	17
Hospital Universitario y Politecnico La Fe	Valencia	Spain	2
Institut Catala D'oncologia	L'Hospitalet de Llobregat	Spain	1
Parc Tauli Hospital Universitari	Sabadell	Spain	1